A retrospective audit of the real‐world safety and effectiveness profile of eptinezumab for treatment‐resistant chronic migraine in Australia
Our findings show that eptinezumab is a safe, well-tolerated migraine prophylactic that decreases monthly migraine and headache days in a small sample of Australian patients with treatment-resistant chronic migraine. Further prospective studies with larger sample sizes and longer follow-up data are needed to confirm findings of this study.
Authors
- Terence John O'Brien (ORCID: https://orcid.org/0000-0002-7198-8621)
- Jayashri Kulkarni (ORCID: https://orcid.org/0000-0002-3875-5623)
- Shobi Sivathamboo (ORCID: https://orcid.org/0000-0003-4638-9579)
- Helmut Butzkueven (ORCID: https://orcid.org/0000-0003-3940-8727)
- Lakshini Gunasekera (ORCID: https://orcid.org/0000-0002-2292-8155)
- Elspeth Hutton (ORCID: https://orcid.org/0000-0002-8543-7767)
- Emma Foster (ORCID: https://orcid.org/0000-0001-8958-3844)
- Shuli Cheng
Institutions
- The University of Melbourne (AU)
- The Alfred Hospital (AU)
- Monash University (AU)
Publication Details
- Journal
- Headache The Journal of Head and Face Pain
- Published
- 2025-12-02
- DOI
- https://doi.org/10.1111/head.70015
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00